Modest Gains for Stocks of Omics, MDx Firms in May; GenMark Jumps, Fluidigm Tumbles | GenomeWeb

NEW YORK (GenomeWeb) – Stocks for firms in the omics and molecular diagnostics market provided a mixed bag for the month of May as the GenomeWeb Daily News Index saw a gain of 2 percent month over month.

Leading the gainers for the month were GenMark Diagnostics (+23 percent), Veracyte (+19 percent), Illumina (+16 percent), and Hologic (+16 percent).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.